Diabetes, Vol 44, Issue 1 16-19, Copyright © 1995 by American Diabetes Association

ARTICLES

Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide

F Kolligs, HC Fehmann, R Goke and B Goke
Department of Internal Medicine, Philipps University of Marburg, Germany.

Glucagon-like peptide 1 (7-37)/(7-36) amide (GLP-1) is derived from the intestinal proglucagon processing. It is considered an important insulin-releasing gut hormone. This study uses exendin (9-39) amide as a GLP-1 receptor antagonist to evaluate the contribution of GLP-1 to the incretin effect. Anesthetized rats were challenged by an intraduodenal glucose infusion to evaluate maximally occurring GLP-1 and gastric inhibitory polypeptide (GIP) plasma levels. Maximal immunoreactive (IR) GLP-1 plasma levels amounted to 10 pmol/l (IR-GIP 11 pmol/l). Exendin (9-39) amide abolished the insulin-stimulatory effect of 60 pmol of GLP-1 or of the GLP-1 agonist exendin-4 (0.5 nmol) injected as bolus, respectively. An intravenous bolus injection of 5.94 nmol of exendin (9-39) amide 3 min before enteral glucose infusion grossly reduced the total insulin secretory response (by 60%) and significantly increased circulating blood glucose levels (P < 0.05). In contrast, the GLP-1 antagonist left the insulin response after an intravenous glucose or glucose plus GIP (60 pmol) load unaltered. Our data support the concept that GLP-1 is an important incretin factor. Exendin (9-39) amide is a useful GLP-1 antagonist for in vivo studies.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. J. Holst The Physiology of Glucagon-like Peptide 1 Physiol Rev, October 1, 2007; 87(4): 1409 - 1439. [Abstract] [Full Text] [PDF]

				T. P. Vahl, M. Tauchi, T. S. Durler, E. E. Elfers, T. M. Fernandes, R. D. Bitner, K. S. Ellis, S. C. Woods, R. J. Seeley, J. P. Herman, et al. Glucagon-Like Peptide-1 (GLP-1) Receptors Expressed on Nerve Terminals in the Portal Vein Mediate the Effects of Endogenous GLP-1 on Glucose Tolerance in Rats Endocrinology, October 1, 2007; 148(10): 4965 - 4973. [Abstract] [Full Text] [PDF]

				T. H Claus, C. Q Pan, J. M Buxton, L. Yang, J. C Reynolds, N. Barucci, M. Burns, A. A Ortiz, S. Roczniak, J. N Livingston, et al. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes J. Endocrinol., February 1, 2007; 192(2): 371 - 380. [Abstract] [Full Text] [PDF]

				R K. Campbell Rationale for Dipeptidyl Peptidase 4 Inhibitors: A New Class of Oral Agents for the Treatment of Type 2 Diabetes Mellitus Ann. Pharmacother., January 1, 2007; 41(1): 51 - 60. [Abstract] [Full Text] [PDF]

				J. C. Parker, K S Lavery, N Irwin, B D Green, B Greer, P Harriott, F P M O'Harte, V A Gault, and P R Flatt Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice. J. Endocrinol., October 1, 2006; 191(1): 93 - 100. [Abstract] [Full Text] [PDF]

				J Schirra, M Nicolaus, R Roggel, M Katschinski, M Storr, H J Woerle, and B Goke Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans Gut, February 1, 2006; 55(2): 243 - 251. [Abstract] [Full Text] [PDF]

				J. J. Meier, G. Kemmeries, J. J. Holst, and M. A. Nauck Erythromycin Antagonizes the Deceleration of Gastric Emptying by Glucagon-Like Peptide 1 and Unmasks Its Insulinotropic Effect in Healthy Subjects Diabetes, July 1, 2005; 54(7): 2212 - 2218. [Abstract] [Full Text] [PDF]

				B D Green, N Irwin, V A Gault, C J Bailey, F P M O'Harte, and P R Flatt Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice J. Endocrinol., May 1, 2005; 185(2): 307 - 317. [Abstract] [Full Text] [PDF]

				K. Masur, E. C. Tibaduiza, C. Chen, B. Ligon, and M. Beinborn Basal Receptor Activation by Locally Produced Glucagon-Like Peptide-1 Contributes to Maintaining {beta}-Cell Function Mol. Endocrinol., May 1, 2005; 19(5): 1373 - 1382. [Abstract] [Full Text] [PDF]

				J. J. Holst and C. Orskov The Incretin Approach for Diabetes Treatment: Modulation of Islet Hormone Release by GLP-1 Agonism Diabetes, December 1, 2004; 53(suppl_3): S197 - S204. [Abstract] [Full Text] [PDF]

				J. J. Holst and J. Gromada Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans Am J Physiol Endocrinol Metab, August 1, 2004; 287(2): E199 - E206. [Abstract] [Full Text] [PDF]

				D. A. D'Alessio and T. P. Vahl Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E882 - E890. [Abstract] [Full Text] [PDF]

				D. J. Drucker Enhancing Incretin Action for the Treatment of Type 2 Diabetes Diabetes Care, October 1, 2003; 26(10): 2929 - 2940. [Abstract] [Full Text] [PDF]

				T. P. Vahl, B. W. Paty, B. D. Fuller, R. L. Prigeon, and D. A. D'Alessio Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on Intravenous Glucose Tolerance and Glucose-Induced Insulin Secretion in Healthy Humans J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1772 - 1779. [Abstract] [Full Text] [PDF]

				K. E. Mayo, L. J. Miller, D. Bataille, S. Dalle, B. Goke, B. Thorens, and D. J. Drucker International Union of Pharmacology. XXXV. The Glucagon Receptor Family Pharmacol. Rev., March 1, 2003; 55(1): 167 - 194. [Abstract] [Full Text] [PDF]

				Y. Li, T. Hansotia, B. Yusta, F. Ris, P. A. Halban, and D. J. Drucker Glucagon-like Peptide-1 Receptor Signaling Modulates beta Cell Apoptosis J. Biol. Chem., January 3, 2003; 278(1): 471 - 478. [Abstract] [Full Text] [PDF]

				G. W. Van Citters, M. Kabir, S. P. Kim, S. D. Mittelman, M. K. Dea, P. L. Brubaker, and R. N. Bergman Elevated Glucagon-Like Peptide-1-(7-36)-Amide, but Not Glucose, Associated with Hyperinsulinemic Compensation for Fat Feeding J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 5191 - 5198. [Abstract] [Full Text] [PDF]

				C. M. B. Edwards, S. A. Stanley, R. Davis, A. E. Brynes, G. S. Frost, L. J. Seal, M. A. Ghatei, and S. R. Bloom Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers Am J Physiol Endocrinol Metab, July 1, 2001; 281(1): E155 - E161. [Abstract] [Full Text] [PDF]

				Y.-H. Choi and G. H. Anderson An Interaction between Hypothalamic Glucagon-Like Peptide-1 and Macronutrient Composition Determines Food Intake in Rats J. Nutr., June 1, 2001; 131(6): 1819 - 1825. [Abstract] [Full Text]

				A. S. Rocca, J. LaGreca, J. Kalitsky, and P. L. Brubaker Monounsaturated Fatty Acid Diets Improve Glycemic Tolerance through Increased Secretion of Glucagon-Like Peptide-1 Endocrinology, March 1, 2001; 142(3): 1148 - 1155. [Abstract] [Full Text] [PDF]

				K. Persson, R. L. Gingerich, S. Nayak, K. Wada, E. Wada, and B. Ahren Reduced GLP-1 and insulin responses and glucose intolerance after gastric glucose in GRP receptor-deleted mice Am J Physiol Endocrinol Metab, November 1, 2000; 279(5): E956 - E962. [Abstract] [Full Text] [PDF]

				J. T. Lewis, B. Dayanandan, J. F. Habener, and T. J. Kieffer Glucose-Dependent Insulinotropic Polypeptide Confers Early Phase Insulin Release to Oral Glucose in Rats: Demonstration by a Receptor Antagonist Endocrinology, October 1, 2000; 141(10): 3710 - 3716. [Abstract] [Full Text] [PDF]

				S. Mojsov Glucagon-like Peptide-1 (GLP-1) and the Control of Glucose Metabolism in Mammals and Teleost Fish Integr. Comp. Biol., April 1, 2000; 40(2): 246 - 258. [Abstract] [Full Text] [PDF]

				R. J. Seeley, S. C. Woods, and D. D'Alessio Editorial: Targeted Gene Disruption in Endocrine Research--The Case of Glucagon-Like Peptide-1 and Neuroendocrine Function Endocrinology, February 1, 2000; 141(2): 473 - 475. [Full Text] [PDF]

				T. J. Kieffer and J. Francis Habener The Glucagon-Like Peptides Endocr. Rev., December 1, 1999; 20(6): 876 - 913. [Abstract] [Full Text]

				B. Ahren and G. Pacini Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice Am J Physiol Endocrinol Metab, December 1, 1999; 277(6): E996 - E1004. [Abstract] [Full Text] [PDF]

				R. P. Boushey, B. Yusta, and D. J. Drucker Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis Am J Physiol Endocrinol Metab, November 1, 1999; 277(5): E937 - E947. [Abstract] [Full Text] [PDF]

				E. Naslund, J. Bogefors, S. Skogar, P. Gryback, H. Jacobsson, J. J. Holst, and P. M. Hellstrom GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans Am J Physiol Regulatory Integrative Comp Physiol, September 1, 1999; 277(3): R910 - R916. [Abstract] [Full Text] [PDF]

				C.-C. Tseng, X.-Y. Zhang, and M. M. Wolfe Effect of GIP and GLP-1 antagonists on insulin release in the rat Am J Physiol Endocrinol Metab, June 1, 1999; 276(6): E1049 - E1054. [Abstract] [Full Text] [PDF]

				V. Serre, W. Dolci, E. Schaerer, L. Scrocchi, D. Drucker, S. Efrat, and B. Thorens Exendin-(9-39) Is an Inverse Agonist of the Murine Glucagon-Like Peptide-1 Receptor: Implications for Basal Intracellular Cyclic Adenosine 3',5'-Monophosphate Levels and {beta}-Cell Glucose Competence Endocrinology, November 1, 1998; 139(11): 4448 - 4454. [Abstract] [Full Text] [PDF]

				P. L. Brubaker, J. Schloos, and D. J. Drucker Regulation of Glucagon-Like Peptide-1 Synthesis and Secretion in the GLUTag Enteroendocrine Cell Line Endocrinology, October 1, 1998; 139(10): 4108 - 4114. [Abstract] [Full Text] [PDF]

				L. A. Scrocchi and D. J. Drucker Effects of Aging and a High Fat Diet on Body Weight and Glucose Tolerance in Glucagon-Like Peptide-1 Receptor-/- Mice Endocrinology, July 1, 1998; 139(7): 3127 - 3132. [Abstract] [Full Text] [PDF]

				L. C. Fung, C. Chisholm, and G. R. Greenberg Glucagon-Like Peptide-1-(7-36) Amide and Peptide YY Mediate Intraduodenal Fat-Induced Inhibition of Acid Secretion in Dogs Endocrinology, January 1, 1998; 139(1): 189 - 194. [Abstract] [Full Text] [PDF]

				M. A. Nauck, U. Niedereichholz, R. Ettler, J. J. Holst, C. Orskov, R. Ritzel, and W. H. Schmiegel Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans Am J Physiol Endocrinol Metab, November 1, 1997; 273(5): E981 - E988. [Abstract] [Full Text] [PDF]

				A. Bozkurt, M. L. Villanueva-Penacarrillo, and N. B. Ulusoy Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms Am J Physiol Gastrointest Liver Physiol, October 1, 1997; 273(4): G920 - G927. [Abstract] [Full Text] [PDF]

				L. Baggio, F. Adatia, T. Bock, P. L. Brubaker, and D. J. Drucker Sustained Expression of Exendin-4 Does Not Perturb Glucose Homeostasis, beta -Cell Mass, or Food Intake in Metallothionein-Preproexendin Transgenic Mice J. Biol. Chem., October 27, 2000; 275(44): 34471 - 34477. [Abstract] [Full Text] [PDF]

				C. F. Deacon, A. Plamboeck, S. Moller, and J. J. Holst GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion Am J Physiol Endocrinol Metab, April 1, 2002; 282(4): E873 - E879. [Abstract] [Full Text] [PDF]